147 related articles for article (PubMed ID: 14710532)
1. [Schizophrenia and drug abuse: genetic aspects].
Poirier MF
Encephale; 2003 Sep; 29(Pt 2):S23-7. PubMed ID: 14710532
[No Abstract] [Full Text] [Related]
2. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
Guillin O; Demily C; Thibaut F
Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
[TBL] [Abstract][Full Text] [Related]
3. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse.
Jockers-Scherübl MC; Danker-Hopfe H; Mahlberg R; Selig F; Rentzsch J; Schürer F; Lang UE; Hellweg R
Neurosci Lett; 2004 Nov; 371(1):79-83. PubMed ID: 15500971
[TBL] [Abstract][Full Text] [Related]
4. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms.
Numata S; Ueno S; Iga J; Yamauchi K; Hongwei S; Ohta K; Kinouchi S; Shibuya-Tayoshi S; Tayoshi S; Aono M; Kameoka N; Sumitani S; Tomotake M; Kaneda Y; Taniguchi T; Ishimoto Y; Ohmori T
Neurosci Lett; 2006 Jun; 401(1-2):1-5. PubMed ID: 16533563
[TBL] [Abstract][Full Text] [Related]
5. Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway.
Guillin O; Griffon N; Diaz J; Le Foll B; Bezard E; Gross C; Lammers C; Stark H; Carroll P; Schwartz JC; Sokoloff P
Int Rev Neurobiol; 2004; 59():425-44. PubMed ID: 15006497
[No Abstract] [Full Text] [Related]
6. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
[TBL] [Abstract][Full Text] [Related]
7. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia.
Renou J; De Luca V; Zai CC; Bulgin N; Remington G; Meltzer HY; Lieberman JA; Le Foll B; Kennedy JL
Mol Psychiatry; 2007 Dec; 12(12):1058-60. PubMed ID: 18043709
[No Abstract] [Full Text] [Related]
8. [Functional role of dopamine D3 receptor in schizophrenia].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
[TBL] [Abstract][Full Text] [Related]
9. Effects of brain-derived neurotrophic factor-catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms.
Han DH; Park DB; Choi TY; Joo SY; Lee MK; Park BR; Nishimura R; Chu CC; Renshaw PF
Neuroreport; 2008 Jul; 19(11):1155-8. PubMed ID: 18596619
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical and genetic aspects of pathogenesis of schizophrenia].
Kambarova DK; Golubev AG
Zh Evol Biokhim Fiziol; 2011; 47(5):348-57. PubMed ID: 22145315
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males.
Cheng CY; Hong CJ; Yu YW; Chen TJ; Wu HC; Tsai SJ
Brain Res Mol Brain Res; 2005 Oct; 140(1-2):86-90. PubMed ID: 16109452
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
[TBL] [Abstract][Full Text] [Related]
13. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls.
Rentzsch J; Penzhorn A; Kernbichler K; Plöckl D; Gómez-Carrillo de Castro A; Gallinat J; Jockers-Scherübl MC
Exp Neurol; 2007 May; 205(1):241-9. PubMed ID: 17368620
[TBL] [Abstract][Full Text] [Related]
14. [Gene/environment interactions in schizophrenia].
Krebs MO
Encephale; 2006 Oct; 32(5 Pt 4):S884-6; discussion S887-8. PubMed ID: 17119495
[No Abstract] [Full Text] [Related]
15. [New pharmacological approaches to the treatment of schizophrenia].
Uzbay IT
Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis.
Vogel M; Busse S; Freyberger HJ; Grabe HJ
Med Hypotheses; 2006; 67(2):354-8. PubMed ID: 16540254
[TBL] [Abstract][Full Text] [Related]
17. Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons.
Takahashi T; Suzuki M; Tsunoda M; Kawamura Y; Takahashi N; Tsuneki H; Kawasaki Y; Zhou SY; Kobayashi S; Sasaoka T; Seto H; Kurachi M; Ozaki N
Neurosci Lett; 2008 Apr; 435(1):34-9. PubMed ID: 18325670
[TBL] [Abstract][Full Text] [Related]
18. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
Kang SG; Choi JE; An H; Lim SW; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Lee MS; Joe SH; Jung IK; Kim L
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1545-8. PubMed ID: 18602732
[TBL] [Abstract][Full Text] [Related]
19. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia.
Gratacòs M; González JR; Mercader JM; de Cid R; Urretavizcaya M; Estivill X
Biol Psychiatry; 2007 Apr; 61(7):911-22. PubMed ID: 17217930
[TBL] [Abstract][Full Text] [Related]
20. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
